InGeneron Announces Critical In-Depth Analysis of the Results from a Recently Published 480-Patient Phase III Knee Osteoarthritis Trial

The data presentation and discussion in the recently published MILES study yield more questions than answers regarding the optimal treatment for knee osteoarthritis

InGeneron, Inc., a clinical stage biotechnology company, announces a critical in-depth analysis of the results from a 480-patient Phase III knee osteoarthritis (OA) trial that was recently published in the Journal Nature Medicine on November 2nd, 2023. The original study, entitled “Cell based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial”, aimed to investigate the therapeutic effectiveness of InGeneron’s regenerative cell therapy in comparison to two other orthobiologic treatments and the conventional corticosteroid injection for knee OA.

Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.

A critical in-depth analysis titled “Management of Knee Pain in Osteoarthritis with Orthobiologics and Corticosteroid Injection: More Questions than Answers” was published on November 16th by Drs. Christoph Schmitz, Christopher Alt and Eckhard U. Alt.

The authors came to the following conclusion (cited from the abstract):

“The [original] study concluded that, one-year post-treatment, all orthobiologic therapies examined were equivalent in effectiveness to each other and to corticosteroid injections.

“While we commend the scope and methodological rigor of the trial, the publication could be enhanced by a more comprehensive presentation of data to support the conclusions drawn. Particularly, the omission of baseline data for primary outcomes, the missing context to evaluate absolute values, and the lack of discussion regarding interindividual variability is of concern.

“Also of note, are the surprisingly positive results reported for patients treated with corticosteroid injections, which severely contradict established literature findings (e.g., Orchard, Osteoarthritis Cartilage 2023;31(2):142-143); and are as such less suitable to support the supposed main finding of the study that orthobiologics would not be more helpful than corticosteroid injections. The release of supplementary data could facilitate a comprehensive understanding and better utilization of this rich dataset.”

Specifically, the in-depth analysis raises the question whether a more differentiated analysis of patient sub-populations might have found a different result. The analysis suggests, “Additional sub-group analyses would have provided important information not only for the main conclusion of the Nature Medicine publication, but also for the design of follow-up studies.” Such a sub-group analysis seems necessary considering the rise of knee replacements in most countries as knee OA prevalence itself is driven by longer life expectancies worldwide (Orchard, 2023).

Publication Details

Citation: Schmitz, C., Alt, C. & Alt, E.U. Management of knee pain in osteoarthritis with orthobiologics and corticosteroid injection: more questions than answers. Preprints doi:10.20944/preprints202311.1081.v1

About the Transpose® RT System and Current Clinical Trials

InGeneron’s Transpose® RT cell therapy platform consists of a processing unit, a set of disposables, and Matrase™, a proprietary enzyme mixture. The platform allows the isolation of regenerative cells from the patients’ own adipose tissue at point-of-care for same-day treatment. The cells are re-administered into the patient’s damaged tissue by injection under ultrasound or fluoroscopic guidance.

The Transpose® RT System is being investigated in several FDA-approved clinical trials and is currently available in the U.S. for research use only. More information on InGeneron’s actively enrolling clinical trials can be found at www.clinicaltrials.gov under the identifiers NCT03752827, NCT03513731, and NCT03503305.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).

By using this website you agree to accept Medical Device News Magazine Privacy Policy